SCHEMBL21708009

SCHEMBL21708009

CCOC(=O)c1csc(Nc2ccc(C)cc2Br)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
MAPT P10636 6/20 0.53
NPSR1 Q6W5P4 4/20 0.53
LMNA P02545 4/20 0.53
KDM4E B2RXH2 4/20 0.53
TDP1 Q9NUW8 2/20 0.53
RAB9A P51151 6/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
NPC1 O15118 5/20 0.52
GAA P10253 2/20 0.52
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
HSD17B10 Q99714 1/20 0.49
HSP90AA1 P07900 2/20 0.49
MAPK1 P28482 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL10669503 0.86 CYP1A2 (0.54) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL15349192 0.84 CYP1A2 (0.54) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL31436988 0.81 CYP1A2 (0.54) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL21708021 0.80 MAPT (0.68) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL2831045 0.80 L3MBTL1 (0.62) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL21708015 0.79 MAPT (0.67) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL10464759 0.78 RAB9A (0.62) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL21708026 0.77 SMN1; SMN2 (0.59) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL21708013 0.77 MAPT (0.67) CYP1A2CYP2C19MAPTNPSR1LMNA
SCHEMBL14742578 0.76 CYP1A2 (0.56) CYP1A2CYP2C19MAPTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A CYP1A2 3477/4885CYP2C19 3845/4885MAPT 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.